E-LIB Suche - Ergebnisse für: Ryosuke Kuribayashi

1

Overexpression of Heat Shock Protein 70 Restores the Struct..:

Yoshiaki Tabuchi ; Ryosuke Kuribayashi ; Ichiro Takasaki...
Cell Stress & Chaperones. 11 (2006) 3 - p. 259-267 , 2006

Link: https://www.jstor.org/st..

2

Overexpression of heat shock protein 70 restores the struct..:

Yoshiaki Tabuchi ; Ryosuke Kuribayashi ; Ichiro Takasaki... , 2006

Link: https://bioone.org/doi/1..

3

The bioequivalence study design recommendations for immedia..:

Fernandes, Eduardo Agostinho Freitas ; Oudtshoorn, Joy van ; Tam, Andrew...
Journal of Pharmacy & Pharmaceutical Sciences. 27 (2024) - p. , 2024

Link: https://doi.org/10.3389/..

4

Survey of Data Package and Sample Size of Comparative Clini..:

Kuribayashi, Ryosuke ; Hariu, Aya ; Nakano, Ayuki.
Pharmaceutical Medicine. 38 (2024) 3 - p. 225-239 , 2024

Link: https://doi.org/10.1007/..

5

Historical Overview of Regulatory Approvals and PMDA Assess..:

Kuribayashi, Ryosuke ; Nakano, Ayuki ; Hariu, Aya..
BioDrugs. 37 (2023) 4 - p. 443-451 , 2023

Link: https://doi.org/10.1007/..

6

First Approval of Generic Mometasone Furoate Nasal Suspensi..:

Kuribayashi, Ryosuke ; Kasuga, Miho ; Kuwana, Kimika.
Therapeutic Innovation & Regulatory Science. , 2022

Link: https://doi.org/10.1007/..

7

A Survey of the Criteria Used for the Selection of Alternat..:

Tam, Andrew ; Garcia-Arieta, Alfredo ; Abalos, Ivana...
Journal of Pharmacy & Pharmaceutical Sciences. 25 (2022) - p. 323-339 , 2022

Link: https://doi.org/10.18433..

8

Requirements for Additional Strength Biowaivers for Modifie..:

Roost, Matthias Shona ; Potthast, Henrike ; Walther, Chantal...
Journal of Pharmacy & Pharmaceutical Sciences. 24 (2021) - p. 548-562 , 2021

Link: https://doi.org/10.18433..

9

Generic Drug Product Development in Japan: Regulatory Updat..:

Kasuga, Miho ; Kuribayashi, Ryosuke ; Ogawa, Takumi...
European Journal of Drug Metabolism and Pharmacokinetics. 46 (2021) 6 - p. 711-719 , 2021

Link: https://doi.org/10.1007/..

10

A Survey of the Regulatory Requirements for the Waiver of I..:

Garcia Arieta, Alfredo ; Simon, Craig ; Tam, Andrew...
Journal of Pharmacy & Pharmaceutical Sciences. 24 (2021) - p. 113-126 , 2021

Link: https://doi.org/10.18433..

11

Current Regulation for Bioequivalence Evaluations of Generi..:

Myoenzono, Aya ; Kuribayashi, Ryosuke ; Yamaguchi, Toru..
European Journal of Drug Metabolism and Pharmacokinetics. 45 (2020) 6 - p. 697-702 , 2020

Link: https://doi.org/10.1007/..

12

Modernization and Strengthening of Bioequivalence Guideline..:

Kuribayashi, Ryosuke ; Yamaguchi, Toru ; Takagi, Kazunori
Clinical Pharmacokinetics. 60 (2020) 2 - p. 145-151 , 2020

Link: https://doi.org/10.1007/..

13

First approval of generic dry powder inhaler drug products ..:

Kuribayashi, Ryosuke ; Myoenzono, Aya
Drug Delivery and Translational Research. 10 (2020) 5 - p. 1517-1519 , 2020

Link: https://doi.org/10.1007/..

14

The Requirements for Additional Strength Biowaivers for Imm..:

Crane, Christopher ; Santos, Gustavo Mendes Lima ; Fernandes, Eduardo Agostinho Freitas...
Journal of Pharmacy & Pharmaceutical Sciences. 22 (2019) - p. 486-500 , 2019

Link: https://doi.org/10.18433..

15

Current Understanding of the Equivalence Evaluations for In..:

Kuribayashi, Ryosuke ; Myoenzono, Aya ; Takagi, Kazunori.
European Journal of Drug Metabolism and Pharmacokinetics. 44 (2019) 6 - p. 743-745 , 2019

Link: https://doi.org/10.1007/..